We are live on ! Find out more
JNCE

Jounce Therapeutics, Inc. Common Stock
JNCE

Delisted

JNCE was delisted on the 3rd of May, 2023.

Back to rankings

100 hedge funds and large institutions have $221M invested in Jounce Therapeutics, Inc. Common Stock in 2019 Q4 according to their latest regulatory filings, with 32 funds opening new positions, 30 increasing their positions, 24 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more first-time investments, than exits

New positions opened: 32 | Existing positions closed: 8

175% more capital invested

Capital invested by funds: $80.2M → $221M (+$140M)

30% more funds holding

Funds holding: 77 → 100 (+23)

25% more repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 24

4% more call options, than puts

Call options by funds: $876K | Put options by funds: $839K

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

Holders
100
Holders Change
+23
Holders Change %
+29.87%
% of All Funds
1.97%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
32
Increased
30
Reduced
24
Closed
8
Calls
$876K
Puts
$839K
Net Calls
+$37K
Net Calls Change
-$20K

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$2.71M
2
Marshall Wace
Marshall Wace
United Kingdom
+$2.56M
3
Renaissance Technologies
Renaissance Technologies
New York
+$1.95M
4
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$1.4M
5
Point72 Asset Management
Point72 Asset Management
Connecticut
+$1.08M

Top Sellers

Rank Fund Capital Flow
1
Wellington Management Group
Wellington Management Group
Massachusetts
-$4.69M
2
JP Morgan Chase
JP Morgan Chase
New York
-$1M
3
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$719K
4
Millennium Management
Millennium Management
New York
-$510K
5
SO
STRS Ohio
Ohio
-$469K
Name Holding Trade Value Shares
Change 		Change in
Stake
Two Sigma Advisers
26
Two Sigma Advisers
New York
$1.03M -$123K -22,800 -16%
Invesco
27
Invesco
Georgia
$1.02M +$633K +117,169 New
Goldman Sachs
28
Goldman Sachs
New York
$969K -$140K -25,823 -19%
EIM
29
Essex Investment Management
Massachusetts
$945K – – –
QI
30
QS Investors
New York
$878K -$8.11K -1,500 -1%
Prudential Financial
31
Prudential Financial
New Jersey
$863K -$181K -33,462 -25%
EI
32
EAM Investors
California
$748K +$463K +85,658 New
Russell Investments Group
33
Russell Investments Group
United Kingdom
$698K +$262K +48,470 +143%
Axa
34
Axa
France
$643K +$398K +73,600 New
TI
35
Trexquant Investment
Connecticut
$598K +$370K +68,528 New
SO
36
STRS Ohio
Ohio
$593K -$469K -86,800 -56%
DCM
37
Dupont Capital Management
Delaware
$587K +$364K +67,276 New
SFM
38
Systematic Financial Management
New Jersey
$577K +$357K +66,055 New
Millennium Management
39
Millennium Management
New York
$561K -$510K -94,294 -59%
N
40
Nuveen
North Carolina
$507K -$134K -24,763 -30%
Wells Fargo
41
Wells Fargo
California
$490K +$60K +11,101 +25%
CANY
42
Caxton Associates (New York)
New York
$489K +$303K +56,029 New
Susquehanna International Group
43
Susquehanna International Group
Pennsylvania
$422K +$152K +28,084 +139%
Morgan Stanley
44
Morgan Stanley
New York
$414K +$8.79K +1,627 +4%
First Manhattan
45
First Manhattan
New York
$384K – – –
AllianceBernstein
46
AllianceBernstein
Tennessee
$368K – – –
Deutsche Bank
47
Deutsche Bank
Germany
$348K -$235K -43,492 -52%
SEI Investments
48
SEI Investments
Pennsylvania
$335K +$208K +38,411 New
D.E. Shaw & Co
49
D.E. Shaw & Co
New York
$298K -$719K -132,970 -80%
AIM
50
Alambic Investment Management
California
$258K +$35.8K +6,632 +29%
1
2
3 4 5

JNCE Hedge Fund Activity: Q4 2019 in Review

100 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Jounce Therapeutics, Inc. Common Stock (JNCE) for Q4 2019, worth a combined $221M — up 175% from $80.2M a quarter earlier.

Buyers outnumbered sellers: 32 funds opened new JNCE positions and 8 closed out — a net gain of 24 holders — while 30 added to existing stakes and 24 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $2.71M. The largest seller was Wellington Management Group, exiting entirely with an estimated $4.69M sold.

  • 100 institutional investors held Jounce Therapeutics, Inc. Common Stock (JNCE) as of Q4 2019, up from 77 in Q3 2019.
  • Funds reported $221M of Jounce Therapeutics, Inc. Common Stock stock for Q4 2019, up 175% quarter-over-quarter.
  • 32 funds opened new Jounce Therapeutics, Inc. Common Stock positions in Q4 2019 and 8 closed out, a net change of +24 holders.
  • The largest Jounce Therapeutics, Inc. Common Stock buyer in Q4 2019 was Fidelity Investments, an estimated $2.71M added.
  • The largest Jounce Therapeutics, Inc. Common Stock seller in Q4 2019 was Wellington Management Group, an estimated $4.69M sold.

Based on aggregated 13F filings for Q4 2019.